Based on 13 Wall Street analysts offering 12 month price targets for Crinetics Pharmaceuticals in the last 3 months. The average price target is $58.23 with a high forecast of $80.00 and a low forecast of $47.00. The average price target represents a 21.24% change from the last price of $48.03.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","81":"$81","30.75":"$30.8","47.5":"$47.5","64.25":"$64.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$58.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$47.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,30.75,47.5,64.25,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.53,50.027692307692305,52.52538461538462,55.02307692307692,57.52076923076923,60.01846153846154,62.51615384615384,65.01384615384615,67.51153846153846,70.00923076923077,72.50692307692307,75.00461538461539,77.50230769230768,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.53,48.35307692307693,49.176153846153845,49.99923076923077,50.82230769230769,51.645384615384614,52.46846153846154,53.29153846153846,54.114615384615384,54.9376923076923,55.76076923076923,56.58384615384615,57.40692307692307,{"y":58.23,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.53,47.48923076923077,47.44846153846154,47.40769230769231,47.36692307692308,47.326153846153844,47.285384615384615,47.244615384615386,47.20384615384616,47.16307692307692,47.12230769230769,47.081538461538464,47.04076923076923,{"y":47,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.89,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.35,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.01,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.68,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.7,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.44,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.86,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.7,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.74,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.76,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.08,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.03,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.53,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$80.00

Average Price Target$58.23

Lowest Price Target$47.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

JMP Securities

xxxxxxxxxxxxx

Reiterated

03/27/24

xxxxxxxxxxxxxxxxxx

H.C. Wainwright

xxxxxxxxxxxxx

Assigned

03/20/24

xxxxxxxxxxxxxxxxxx

Oppenheimer

xxxxxxxxxxxxx

Reiterated

03/20/24

xxxxxxxxxxxxxxxxxx

JonesTrading

xxxxxxxxxxxxx

Reiterated

03/19/24

xxxxxxxxxxxxxxxxxx

Robert W. Baird

xxxxxxxxxxxxx

Reiterated

03/19/24

xxxxxxxxxxxxxxxxxx

Leerink Partners

xxxxxxxxxxxxx

Reiterated

03/19/24

xxxxxxxxxxxxxxxxxx

LifeSci Capital

xxxxxxxxxxxxx

Reiterated

03/13/24

xxxxxxxxxxxxxxxxxx

Piper Sandler

xxxxxxxxxxxxx

Assigned

03/13/24

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Reiterated

03/13/24

xxxxxxxxxxxxxxxxxx

Citi

xxxxxxxxxxxxx

Initiated

03/06/24

Joshua Schimmer

Cantor Fitzgerald

$65.00

Buy

35.33%

Upside

Reiterated

03/04/24

Crinetics (CRNX) PT Raised to $65 at Cantor FitzgeraldCantor Fitzgerald analyst Josh Schimmer raised the price target on Crinetics (NASDAQ: CRNX) to $65.00 (from $50.00) while maintaining a Overweight rating.

Gavin Clark-Gartner

Evercore ISI

$54.00

Buy

12.43%

Upside

Reiterated

02/12/24

Crinetics price target raised to $54 from $51 at Evercore ISICrinetics price target raised to $54 from $51 at Evercore ISI

Jeffrey Hung

Morgan Stanley

$50.00

Buy

4.10%

Upside

Initiated

01/16/24

Crinetics initiated with an Overweight at Morgan StanleyCrinetics initiated with an Overweight at Morgan Stanley

Dennis Ding

Jefferies

$35.00

Hold

-27.13%

Downside

Initiated

12/20/23

Jefferies starts Crinetics (CRNX) at HoldJefferies initiates coverage on Crinetics (NASDAQ: CRNX) with a Hold rating and a price target of $35.00.

Best Analysts Covering Crinetics Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy CRNX and Sell After:

1 Month

Yasmeen RahimiPiper Sandler

Success Rate

9/12 ratings generated profit

Average Return

+5.27%

assigned a buy rating last month

Copying Yasmeen Rahimi's trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +5.27% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Douglas TsaoH.C. Wainwright

Success Rate

17/22 ratings generated profit

Average Return

+11.41%

assigned a buy rating 27 days ago

Copying Douglas Tsao's trades and holding each position for 3 Months would result in 77.27% of your transactions generating a profit, with an average return of +11.41% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Yasmeen RahimiPiper Sandler

Success Rate

11/12 ratings generated profit

Average Return

+65.47%

assigned a buy rating last month

Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +65.47% per trade.

2 Years

Jonathan WollebenJMP Securities

Success Rate

22/22 ratings generated profit

Average Return

+105.74%

reiterated a buy rating 20 days ago

Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +105.74% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRNX Analyst Recommendation Trends

Rating

Nov 23

Dec 23

Jan 24

Feb 24

Mar 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRNX has received 34 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CRNX average Analyst price target in the past 3 months is $58.23.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

CRNX Financial Forecast

CRNX Earnings Forecast

Next quarter’s earnings estimate for CRNX is -$0.81 with a range of -$0.94 to -$0.68. The previous quarter’s EPS was -$0.90. CRNX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.50% of the time in the same period. In the last calendar year CRNX has Underperformed its overall industry.

CRNX Sales Forecast

Next quarter’s sales forecast for CRNX is $200.00K with a range of $0.00 to $1.00M. The previous quarter’s sales results were $0.00. CRNX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.18% of the time in the same period. In the last calendar year CRNX has Underperformed its overall industry.

CRNX Stock Forecast FAQ

What is CRNX’s average 12-month price target, according to analysts?

Based on analyst ratings, Crinetics Pharmaceuticals’s 12-month average price target is $58.23.

What is CRNX’s upside potential, based on the analysts’ average price target?

Crinetics Pharmaceuticals has 21.24% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRNX a Buy, Sell or Hold?

Crinetics Pharmaceuticals has a conensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Crinetics Pharmaceuticals’s price target?

The average price target for Crinetics Pharmaceuticals is $58.23. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $47.00. The average price target represents 21.24% Increase from the current price of $48.03.

What do analysts say about Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of CRNX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

CRNX Analyst Ratings

CRNX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Crinetics Pharmaceuticals

CRNX Analyst Recommendation Trends

CRNX Financial Forecast

CRNX Earnings Forecast

CRNX Sales Forecast

CRNX Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts